From the Journals

Early palliative care fails to improve QOL in advanced heart failure


 

FROM JAMA INTERNAL MEDICINE

As heart failure care evolves, so must palliative care

Though the study and intervention developed by Dr. Bakitas and colleagues is commendable, it is only somewhat surprising that it did not drastically improve patients’ quality of life, Nathan E. Goldstein, MD, of the Icahn School of Medicine at Mount Sinai in New York, wrote in an accompanying editorial.

He noted several reasons for the lack of improvement, including a large proportion of patients still being in the early stages of the disease. Ultimately, however, he wonders if innovation in heart failure care ultimately impacted the study while it was occurring. Medications and technological advancements evolve rapidly in this field, he said, especially over the course of a 3-year study period.

To continue this work and produce real benefits in patients with advanced heart failure, Dr. Goldstein emphasized the need for “dynamic palliative care interventions that can adapt to the constantly changing landscape of the patient’s needs caused by the underlying nature of the disease, as well as the innovations in the field of cardiology.”

The authors acknowledged their study’s limitations, including data attrition at 16 weeks that was higher than expected – a turn of events they attributed to “unique socioeconomic factors … and lack of regular health care appointments” among some participants. In addition, a minority of patients were unable to stick to the study protocol, which has led the researchers to begin investigating video alternatives to in-person consultation.

The study was supported by the National Institutes of Health/National Institutes of Nursing Research. Four of the authors reported received grants from the National Institutes of Nursing Research outside the submitted work or during the study. Dr. Goldstein reported no conflicts of interest.

SOURCE: Bakitas MA et al. JAMA Intern Med. 2020 July 27. doi: 10.1001/jamainternmed.2020.2861.

Pages

Recommended Reading

DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
MDedge Family Medicine
Dapagliflozin’s T2D renal protection extends to ‘fast decline’ of eGFR
MDedge Family Medicine
Cost of preventable adult hospital stays topped $33 billion in 2017
MDedge Family Medicine
T2D plus heart failure packs a deadly punch
MDedge Family Medicine
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
MDedge Family Medicine
SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’
MDedge Family Medicine
Prior beta-blockers predict extra burden of heart failure in women with ACS
MDedge Family Medicine
Empagliflozin failed to improve exercise capacity in heart failure
MDedge Family Medicine
Psoriatic disease inflammation linked to heart failure
MDedge Family Medicine
Heart damage even after COVID-19 ‘recovery’ evokes specter of later heart failure
MDedge Family Medicine